Clinical trial
Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With…
NCT00085345 · Oncotherapeutics, Industry · Withdrawn
Key facts
| NCT number | NCT00085345 |
|---|---|
| Title | Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | Phase II Study of Melphalan, Arsenic Trioxide, and Ascorbic Acid in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Oncotherapeutics, Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage II Multiple Myeloma, Stage III Multiple Myeloma, Refractory Plasma Cell Neoplasm |
| Intervention type | Drug, Procedure |
| Interventions | arsenic trioxide, ascorbic acid, melphalan, chemosensitization/potentiation, chemotherapy |
| Enrollment | 0 |
| First posted | Jun 11, 2004 |
| Last update posted | Jul 10, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: